Dear Duchenne Community, As you might have seen, the Office of Drug Evaluation I of the FDA provided a Complete Response Letter (CRL) for the application to market ataluren in […]
PTC Therapeutics received a Complete Response Letter from the Food and Drug Administration (FDA) for Ataluren’s New Drug Application (NDA). This means that the FDA has completed its review of […]
The 22nd International Annual Congress of the World Muscle Society took place in St Malo, between October 3 – 7, 2017. There were multiple breaking news stories on Duchenne muscular […]
SAINT MALO, France, Oct. 4, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International Congress of the World Muscle Society, reported that […]
Philadelphia celebrities, prominent leaders and community members to gather for a blinged-out evening benefitting the fight against Duchenne Muscular Dystrophy Philadelphia, PA (October 4, 2017) – CureDuchenne, a national nonprofit […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 4, 2017– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy results showing sustained disease-modifying effects in the MoveDMD trial open-label extension following […]
San Antonio, Texas, October 3, 2017 – Dealing for Duchenne, a charity event to raise funds for research for children afflicted with Duchenne muscular dystrophy, returns to San Antonio on […]
Dear Duchenne Community, On behalf of all of PTC, we want to thank all of you for supporting the advisory committee review of ataluren. As you know, the meeting was […]
Leading a healthy lifestyle is something that any individual should aim towards. For those with Duchenne, making nutritional modifications has the potential to improve their overall health. Research has indicated […]
